U.S. Court Of Appeals For The Federal Circuit Affirms RMMS’s Victory Involving Generic Ibandronate Products

April 11, 2014 | Small Molecules

04/11/2014 On April 11, 2014, the U.S. Court of Appeals for the Federal Circuit affirmed summary judgment of invalidity of the asserted claims of U.S. Patent Nos. 7,718,634 (‘the ‘634 patent’) and 7,410,957 (‘the ‘957 patent’). Plaintiffs brought suit in the U.S. District Court for the District of New Jersey seeking to prevent the firm’s clients, Watson Laboratories, Inc., Actavis, Inc., Watson Pharma, Inc., and Cobalt Laboratories, Inc. (‘Watson’), from launching a generic version of Boniva®. The District Court found the asserted claims of the ‘634 patent and ‘957 patent to be invalid due to obviousness under 35 U.S.C. § 103. The Federal Circuit affirmed that decision. Deanne Mazzochi, William Rakoczy, Paul Molino, Tara Raghavan, and Eric Hunt are counsel for Watson. Lead counsel Deanne Mazzochi argued the case before the Federal Circuit. This victory continues to place RMMS at the forefront of generic challenges to brand pharmaceutical patents.